ALK and angioimmunoblastic T-cell lymphoma: The response according to subtypes were 100% for ALK-ALCL (n=7, CR:57.1%) and SPTCL (n=2, CR:100%), 71.4% (5/7) for PTCL-NOS (CR:57.1%), 50% (1/2) for ALK+ALCL (PR:50%) and 40% (2/5) for AITL (CR:20%).